Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine

Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yiqi, Yang, Gang, Huang, Hua, Fu, Ziyao, Cao, Zhe, Zheng, Lianfang, You, Lei, Zhang, Taiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783994/
https://www.ncbi.nlm.nih.gov/pubmed/33402215
http://dx.doi.org/10.1186/s13046-020-01787-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783994/
https://www.ncbi.nlm.nih.gov/pubmed/33402215
http://dx.doi.org/10.1186/s13046-020-01787-5

Ejemplares similares